Getting to the Root of Leukemia
Joel Rutstein thought he had a death sentence after being diagnosed with AML. A clinical trial saved his life and is changing the way the disease is treated.
read more
Dr. Villalobos named Medical Director of the Cancer Clinical Trials Office
Victor Villalobos, MD, PhD, University of Colorado Cancer Center member and director in the division of sarcoma medical oncology, was recently named the medical director of the Cancer Center Clinical Trials Office (CCTO). “I was humbled and honored to be considered...
read more
With the right care, patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis
Stage IV ALK+ lung cancer patients treated at UCHealth University of Colorado Hospital between 2009 and 2017 had median overall survival of 6.8 years.
read more
CU Cancer Center launches “Lunch and Learn” series
The University of Colorado Cancer Center Education Working Group kicked off its monthly "Lunch and Learn" series in December with a lively presentation on “The History of Cancer” given by Christopher Lieu, MD. Lieu is the CU Cancer Center's deputy associate director...
read more
Opioid use and misuse following treatment for head and neck cancer
Six months after treatment ended, 7 percent of patients remained on opioid pain medications
read more
Can Facebook advertising prevent cancer?
Colorado Cancer Screening Program uses text and social media to reach out with screening information
read more
Colorado’s Heide Ford, PhD, earns R01 grant targeting breast cancer metastasis
NIH R01 grant may help the Ford lab keep breast cancer cells at home in the primary tumor where they are much less dangerous.
read more
Pollyea and Pietras earn endowed chairs in hematology research
Daniel Pollyea, MD, earns Robert H. Allen Chair; Eric Pietras, PhD, receives Cleo Meador/George Ryland Scott Chair
read more
CU Cancer Center Deputy Director: Working together makes everyone better
Being part of an organization focused on a single mission – eliminating cancer and its consequences – is an honor.
read more
State lawmakers visit Anschutz Campus to learn current and future directions for cancer research and care in Colorado
“Today we are talking about hope, but hope itself isn’t a strategy,” said Chacellor Elliman.
read more
Lymph node ratio may predict who lives and dies from oral cavity cancer
Patients with lymph node ratio greater than 10 percent had about 2.5 times greater risk of cancer recurrence and 2.7 times greater risk of death than patients with LNR below 10 percent
read more
Is a selfless caregiver really best for the patient?
Caregiver wellbeing is associated with measurable, physical benefits to the patient
read more
91 percent response rate for venetoclax against newly diagnosed AML in older adults
Colorado researchers are changing how the world treats acute myeloid leukemia
read more
A terrible choice: Cancer treatment or hospice care, but not both
Colorado researchers explore costs, benefits, and experiences of veterans receiving concurrent treatment and hospice care
read more
Four Anschutz Medical Campus researchers, including two CU Cancer Center Investigators, Internationally Recognized as 2018 Highly Cited Researchers
Ross Camidge, MD, PhD and Russel Glasgow, PhD, MS, were recognized for the second consecutive time in 2018 by Clarivate Analytics.
read more
Targeting MC1R in metastatic melanoma
CU study describes a molecule that seeks out melanoma cells, wherever they hide.
read more
$5 million award targets leukemia stem cells
Cancer is crafty. The disease often resists treatment and developing long-lasting, effective therapies is a challenge. University of Colorado Cancer Center investigator Craig, Jordan, PhD, has been awarded a $5 million grant to build on his body of work targeting...
read more
Cancer stem cells get energy from protein, and it’s proving to be their Achilles’ heel
CU Cancer Center study shows that cancer stem cells switch from metabolizing sugar to metabolizing protein. Turning off protein metabolism kills these cells.
read more
Will tarloxotinib finally break the HER2 barrier in lung cancer?
By pairing a potent HER2/EGFR inhibitor with a targeting mechanism specific to tumors, researchers show that tarloxotinib is far more active against lung cancer cell lines than even the most successful existing HER2/EGFR inhibitors.
read more
“An Evening of Hope” for Pancreatic Cancer Research Returns
On November 17, the University of Colorado Anschutz Medical Campus is hosting “An Evening of Hope” with the non-profit Wings of Hope for Pancreatic Cancer Research. This special event raises funds for life-saving pancreatic cancer research at the University of...
read more
Golfers Against Cancer Celebrates 10 years and $1 million dollars for cancer research
In 2009 the Denver Golfers Against Cancer (GAC) Chapter held its first gala to raise money for life-saving cancer research. In 2010, GAC added a golf tournament to accompany the gala. Now, with the support of the two events, the organization has raised over $1 million...
read more
International study finds micro plastics in human waste
Micro plastic has made its way into the human gut. Whether or not this will have an impact on our health needs more research.
read more
New combination treatment flips the switch on melanoma cells
Navitoclax plus A-1210477 not only killed melanoma cells, but also killed the melanoma initiating cells (aka cancer stem cells) that often resist therapy.
read more
Rani Powers hacks common research tool to win top prize at International Society for Computational Biology conference
Rani will defend her PhD dissertation in March 2019, after which, “there are lots of options for what’s next,” she says.
read more
Wells A. Messersmith, MD, recipient of Michaele C. Christian Oncology Development Award and Lecture
Honor given annually to an outstanding researcher in the field of drug development and testing.
read more
Karyn Goodman, MD, named co-chair of NCI Gastrointestinal Cancer Steering Committee
University of Colorado Cancer Center’s Associate Director for Clinical Research, Karyn Goodman, MD, MS, the David and Margaret Turley Grohne Chair in Clinical Cancer, was recently appointed co-chair of the NCI Gastrointestinal Cancer Steering Committee (GISC).
read more
New study looks at effectiveness of combination therapy against refractory, metastatic colon cancer
If colon cancer is caught in its early stages, patients typically have a good chance of living five years past diagnosis, and beyond. However, for patients with late-stage, metastatic colon cancer, the chance drops dramatically, to a five-year survival rate of only...
read more
Karyn Goodman, MD, named co-chair of NCI Gastrointestinal Cancer Steering Committee
CU Cancer Center’s Karyn Goodman, MD, named to position overseeing the direction of GI cancer clinical trials
read more
Cancer stem cells use “normal” genes in abnormal ways
CDK1 directly interacts with Sox2 to keep cancer stem cells “stemmy”
read more
Cancer hijacks the microbiome to glut itself on glucose
Leukemia actively undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.
read more